G+FLAS Life Sciences, a Korean CRISPR/Cas Genome Editing Company, Licenses DNA-Free Genome Editing Technologies

Biospace.com | February 01, 2019

G+FLAS Life Sciences, Inc. (G+FLAS), a CRISPR/Cas genome editing company in South Korea, announced that they licensed two patents regarding Non-GMO ways of plant genome engineering. The licensed DNA-free CRISPR genome editing technologies enable the development of genome-edited crops without using any foreign DNA, previously reported as the first success in Nature Biotechnology by Dr. Choe’s group in 2015. Before the emergence of CRISPR genome editing technology, most genetically-engineered crops were generated by recombinant DNA-mediated GMO technology that heavily depends on a time-consuming process to segregate out the inserted DNA by genetic recombination. Conventional GMO technologies would take 10 years and cost approximately $100 million to obtain the deregulated status. The founder and CEO of G+FLAS Life Sciences, Sunghwa Choe, Ph.D., said “Licensing the DNA-free genome editing technology should create synergy with our CRISPR PLUSTM® gene-editing platform. With the two cutting-edge technologies, G+FLAS will expedite the company’s trait development programs to commercialize higher-yield and more nutritious crop plants in relatively shorter time.”

Spotlight

Biopharmaceutical companies make the medicines that save and improve patients’ lives every day. Patients often rely on medicines to keep their symptoms at bay and allow them to continue to work and live healthy, productive lives. Others rely on medicines to cure their disease or to prevent life-threatening complications that might keep them out of the hospital.

Spotlight

Biopharmaceutical companies make the medicines that save and improve patients’ lives every day. Patients often rely on medicines to keep their symptoms at bay and allow them to continue to work and live healthy, productive lives. Others rely on medicines to cure their disease or to prevent life-threatening complications that might keep them out of the hospital.

Related News

CELL AND GENE THERAPY

IsoPlexis Acquired a Large Portfolio of DNA and RNA Sequencing to Enable Integrated Single-Cell Sequencing and Proteomic Solutions

IsoPlexis | May 26, 2021

IsoPlexis, the leader in functional single-cell proteomics, announced today the acquisition of a large intellectual property portfolio containing 86 patents related to DNA and RNA sequencing. These nucleic acids and sequencing technologies will be immediately integrated with IsoPlexis' single-cell proteomics platforms, enabling a variety of next-generation tests that include numerous 'omic modalities from every single cell. This is the next step in the company's roadmap, enabling researchers to make far earlier connections in their genomic studies, straight to the proteome, which determines each organism's in vivo dynamic biology. The acquired assets will allow IsoPlexis' proprietary proteomics technologies to be integrated with newer proprietary sequencing-based technologies. The asset acquisition adds to IsoPlexis' ongoing efforts to assist its customers in more effectively simplifying complex biology to accelerate the creation of more personalized and curative advanced medicines from bench to bedside. Isoplexis' growing patent portfolio of 153 total patents filed and issued globally will now include sequencing methodologies, allowing for a new level of resolution into the connections between the genome and the proteome of cancer immunology, cell and gene therapy, neurological disease, and other areas. IsoPlexis' proprietary functional proteomics platform is the first to fully characterize and link cellular function to patient outcomes, treatment response, or disease progression using both proteomics and single-cell biology. The single-cell proteomics platform from IsoPlexis, which comprises instruments, chip consumables, and software, offers an end-to-end solution for providing a more complete view of protein function at the cellular level. The platform has been quickly embraced by the top 15 global biopharmaceutical companies in terms of revenue, as well as over half of the comprehensive cancer centers in the United States, to develop more durable therapeutics, overcome therapeutic resistance, and predict patient responses for advanced immunotherapies, cell therapies, gene therapies, vaccines, and regenerative medicines. ABOUT ISOPLEXIS IsoPlexis is a life science technology company that develops solutions to accelerate the development of curative medicines and personalized therapeutics. Our award-winning single-cell proteomics systems reveal unique biological activity in small subsets of cells, allowing researchers to connect to in vivo biology more directly and develop more precise and personalized therapies. Our integrated systems, which were named top innovation or design by Scientist Magazine, Fierce, BIG Innovation, Red Dot, and a variety of other magazines, are used globally to advance the field of single-cell biology into new 'omic possibilities, as our customers generate solutions to overcome the challenges of complex diseases and therapeutics. Our products have been used by researchers all over the world, including the top 15 pharmaceutical companies in the world and 45% of comprehensive cancer centers in the United States.

Read More

Angstrom Bio Launches AMPD™, Platform for High-accuracy, High-frequency, Low-cost COVID-19 and Respiratory Pathogen Testing

Angstrom Bio | October 14, 2020

Angstrom Bio, Inc. today announces the launch of AMPD™, its nanopore sequencing and machine learning powered platform for high-accuracy, high-frequency, low-cost COVID-19 and respiratory pathogen testing. AMPD leverages the extreme resolution and bandwidth of nanopore sequencing to provide the accuracy and volume necessary to detect the earliest stages of exposure to pathogens like SARS-CoV-2 and influenza and to enable schools and places of work to reopen safely and confidently. Angstrom will partner with businesses, schools, and public sector organizations to implement cost-effective testing programs designed to maximize employee and stakeholder safety and to minimize the potential for operational disruption. The company intends to bring more than 1,000,000 results per day online in 2021, at prices that enable nearly any organization to have access to repeated, high-quality testing. "Despite the tremendous progress made in diagnostics since the beginning of the pandemic, it is clear that testing today remains an area plagued by too many tradeoffs between availability, accuracy, and speed, as well as ease of collection, cost, and adaptability," said Carlos F. Santos, Ph.D., Angstrom's CEO. "We designed AMPD to eliminate the need for such tradeoffs. By leveraging the extraordinary resolution and bandwidth of nanopore sequencing and the power of our machine learning-driven diagnostic pipelines, and by rethinking pre-COVID-19 diagnostic workflows, we have been able to design a platform that can provide the extreme scale and accuracy required to meet the unprecedented challenges posed by COVID-19." At the heart of AMPD is a novel nucleotide chemistry and computational biology platform designed to harness the bandwidth and resolution of Oxford Nanopore Technologies' nanopore Third-Generation Sequencing (TGS) systems. Unlike diagnostic systems that rely upon fluorescence-driven workflows for diagnostic analysis, nanopore TGS counts individual DNA molecules that pass through each of hundreds of nano-scale pores in a specially-designed membrane. The combination of single-molecule resolution and parallelism allow for the processing of tens of thousands of diagnostic results per AMPD run, while enabling orders of magnitude greater sensitivity than is currently available. This makes AMPD ideal for parties that require timely access to affordable, repeated testing, but that cannot compromise safety.

Read More

Bio-K Plus International is expanding its portfolio of probiotic products and is launching a new line of functional beverages infused with probiotics

Bio-K | October 22, 2020

Bio-K Plus International Inc. (Bio-K Plus), pioneer in the probiotic sector and leader in the biotech industry, is pleased to announce the launch of its new line of functional beverages, Essential. Focused on offering premium quality probiotics that make a real difference in people's lives around the world, the company is adding the Essential line to its existing Pro and Original lines. In keeping with this tradition of high quality, the Essential line fits perfectly into the active and modern lifestyle of today's consumer, always looking for innovative ways to stay healthy. Bio-K Plus offers a dose of probiotics in the form of fun, delightful and balanced functional beverages. This announcement is the result of more than two years of research and development carried out by Bio-K Plus' experienced team that has developed the best line of functional beverages infused with probiotic bacteria. This project was led by Martin Croteau, Chief Commercial Officer, and was driven by the need to democratize probiotics, making them more accessible for all, and broaden their use to support global health in a more holistic manner.

Read More